Malaty, Irene A.
Martinez-Martin, Pablo
Chaudhuri, K. Ray
Odin, Per
Skorvanek, Matej
Jimenez-Shahed, Joohi
Soileau, Michael J.
Lindvall, Susanna
Domingos, Josefa
Jones, Sarah
Alobaidi, Ali
Jalundhwala, Yash J.
Kandukuri, Prasanna L.
Onuk, Koray
Bergmann, Lars
Femia, Samira
Lee, Michelle Y.
Wright, Jack
Antonini, Angelo
Article History
Received: 26 July 2021
Accepted: 19 January 2022
First Online: 24 January 2022
Declarations
:
: The Disease Specific Programme was conducted in accordance with the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct. The study protocol (reference number AG8689) was submitted to the Western Institutional Review Board, and an ethics waiver was provided as it was determined that ethics approval was not required for this study. All data were collected following procedures with ethics committee approval, and data were fully de identified prior to receipt by Adelphi Real World. The respondents provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. All data, i.e. methodology, materials, data, and data analysis, that support the findings of this survey are the intellectual property of Adelphi Real World. As such no administrative permissions were required to access and use the data.
: Not applicable.
: IAM has participated in research funded by Parkinson Foundation, Tourette Association of America, Dystonia Coalition, AbbVie, Biogen, Boston Scientific, Eli Lilly, Impax, Neuroderm, Prilenia, Revance, and Teva but has no owner interest in any pharmaceutical company. She has received travel compensation or honoraria from Cleveland Clinic, Parkinson Foundation, Tourette Association, and International Association of Parkinsonism and Related Disorders and royalties from Robert Rose Publishers; PMM has received honoraria from Editorial Viguera and Takeda Pharmaceuticals for lecturing in courses; from Britannia for writing an article in their Parkinson’s Disease Medical Journal-Kinetic; and from the International Parkinson and Movement Disorder Society (MDS) for management of the Program on Rating Scales. Grants from the MDS for development and validation of the MDS-NMS; SAJ has no relevant disclosures; KRC has received educational funding from UCB, and honoraria for sponsored symposiums from UCB, AbbVie, Britannia, US Worldmeds, Otsuka, Medtronic, Zambon and acted as a consultant for AbbVie, UCB, Britannia, Medtronic and Mundipharama; JJ-S has received consulting fees from Teva, Nuvelution, Bracket, Amneal, Revance, AbbVie, CNS Ratings, St. Jude Medical, Medtronic and research funding from Impax; PO has received compensations for consultancy and speaker related activities from AbbVie, Bial, Britannia, Ever Pharma, Lobsor, Nordic Infucare, Stada, and Zambon. Odin has received royalties from Uni-Med Verlag; MS received speakers’ honoraria and/or consultation fees from AbbVie, Boston Scientific, Desitin, Ever Pharma, Krka, Medtronic and Sandoz, he received support from the IBM and Slovak grant agencies under contracts APVV-18-0547 and VEGA 1/0596/19 and the Operational Programme Integrated Infrastructure, funded by the ERDF under No. ITMS2014+:313011 V455; MJS has received honoraria and/or consultation fees from AbbVie, Abbott, Acorda Therapeutics, Amneal, Teva, Sunovion, Neurocrine, Medtronic, and Merz. He has also received research compensation from Cerevel and AbbVie; SL declares no relevant conflict of interest to present study; JD declares no relevant conflict of interest to present study; AlA, YJJ, PLK, KO, LB, SF, and MYL are employees of AbbVie and may own stocks/shares in the company; JW is an employee of Adelphi Real World, a consulting company that was hired by AbbVie to perform analyses on the Adelphi Disease Specific Programme database; AnA has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling.